Which has stronger valuation and earnings, OCS or ABEO?

Abeona Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 448.25 -$119.44M -$2.13 N/A Abeona Therapeutics $5.82M 53.46 $71.18M $0.97 5.63

Is OCS or ABEO more profitable?

Abeona Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Abeona Therapeutics' return on equity of -53.98% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Abeona Therapeutics N/A -53.98% -38.52%

Does the media prefer OCS or ABEO?

In the previous week, Oculis had 14 more articles in the media than Abeona Therapeutics. MarketBeat recorded 17 mentions for Oculis and 3 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.46 beat Oculis' score of -0.25 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ABEO or HROW?

In the previous week, Abeona Therapeutics and Abeona Therapeutics both had 3 articles in the media. Abeona Therapeutics' average media sentiment score of 0.46 beat Harrow's score of 0.06 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, COAG or ABEO?

Abeona Therapeutics has higher revenue and earnings than Hemab Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Abeona Therapeutics $5.82M 53.46 $71.18M $0.97 5.63

Is COAG or ABEO more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Abeona Therapeutics N/A -53.98% -38.52%

Does the media prefer COAG or ABEO?

In the previous week, Abeona Therapeutics had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 3 mentions for Abeona Therapeutics and 2 mentions for Hemab Therapeutics. Abeona Therapeutics' average media sentiment score of 0.46 beat Hemab Therapeutics' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor WVE or ABEO?

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 3 articles in the media. Abeona Therapeutics' average media sentiment score of 0.46 beat WAVE Life Sciences' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abeona Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABEO or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Maplight Therapeutics N/A N/A N/A

Does the media refer more to ABEO or MPLT?

In the previous week, Abeona Therapeutics had 2 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Maplight Therapeutics. Abeona Therapeutics' average media sentiment score of 0.46 beat Maplight Therapeutics' score of -0.16 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Abeona Therapeutics (ABEO) Competitors

$5.46 -0.36 (-6.19%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$5.50 +0.04 (+0.73%)

As of 06/5/2026 05:38 PM Eastern

Compare

ABEO vs. OCS, HROW, COAG, WVE, and MPLT

Should you buy Abeona Therapeutics stock or one of its competitors? MarketBeat compares Abeona Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abeona Therapeutics include Oculis (OCS), Harrow (HROW), Hemab Therapeutics (COAG), WAVE Life Sciences (WVE), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Abeona Therapeutics compare to Oculis?

Oculis (NASDAQ:OCS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

22.3% of Oculis shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	448.25	-$119.44M	-$2.13	N/A
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 241.96%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 247.99%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Oculis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, Oculis had 14 more articles in the media than Abeona Therapeutics. MarketBeat recorded 17 mentions for Oculis and 3 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.46 beat Oculis' score of -0.25 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Abeona Therapeutics' return on equity of -53.98% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Abeona Therapeutics beats Oculis on 12 of the 16 factors compared between the two stocks.

How does Abeona Therapeutics compare to Harrow?

Abeona Therapeutics (NASDAQ:ABEO) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Abeona Therapeutics and Abeona Therapeutics both had 3 articles in the media. Abeona Therapeutics' average media sentiment score of 0.46 beat Harrow's score of 0.06 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Abeona Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Harrow	-5.57%	19.59%	2.26%

Abeona Therapeutics has higher earnings, but lower revenue than Harrow. Harrow is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63
Harrow	$272.30M	4.54	-$5.14M	-$0.41	N/A

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 247.99%. Harrow has a consensus target price of $69.43, indicating a potential upside of 109.19%. Given Abeona Therapeutics' higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Abeona Therapeutics beats Harrow on 9 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Hemab Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Abeona Therapeutics	N/A	-53.98%	-38.52%

Abeona Therapeutics has higher revenue and earnings than Hemab Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63

80.6% of Abeona Therapeutics shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hemab Therapeutics currently has a consensus target price of $41.75, indicating a potential upside of 65.02%. Abeona Therapeutics has a consensus target price of $19.00, indicating a potential upside of 247.99%. Given Abeona Therapeutics' higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Abeona Therapeutics had 1 more articles in the media than Hemab Therapeutics. MarketBeat recorded 3 mentions for Abeona Therapeutics and 2 mentions for Hemab Therapeutics. Abeona Therapeutics' average media sentiment score of 0.46 beat Hemab Therapeutics' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Abeona Therapeutics beats Hemab Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Abeona Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

WAVE Life Sciences presently has a consensus price target of $27.25, indicating a potential upside of 375.57%. Abeona Therapeutics has a consensus price target of $19.00, indicating a potential upside of 247.99%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe WAVE Life Sciences is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, WAVE Life Sciences and WAVE Life Sciences both had 3 articles in the media. Abeona Therapeutics' average media sentiment score of 0.46 beat WAVE Life Sciences' score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abeona Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	25.80	-$204.38M	-$1.06	N/A
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63

Abeona Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Abeona Therapeutics' return on equity of -53.98% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Abeona Therapeutics	N/A	-53.98%	-38.52%

WAVE Life Sciences has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats WAVE Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Abeona Therapeutics compare to Maplight Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

80.6% of Abeona Therapeutics shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Abeona Therapeutics has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Abeona Therapeutics presently has a consensus target price of $19.00, suggesting a potential upside of 247.99%. Maplight Therapeutics has a consensus target price of $37.78, suggesting a potential upside of 34.87%. Given Abeona Therapeutics' higher possible upside, analysts plainly believe Abeona Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Abeona Therapeutics had 2 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Maplight Therapeutics. Abeona Therapeutics' average media sentiment score of 0.46 beat Maplight Therapeutics' score of -0.16 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maplight Therapeutics' return on equity of 0.00% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Abeona Therapeutics beats Maplight Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Abeona Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABEO vs. The Competition

Export

Metric	Abeona Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$311.19M	$3.34B	$6.68B	$11.99B
Dividend Yield	N/A	2.31%	2.67%	5.55%
P/E Ratio	5.63	19.02	24.06	23.63
Price / Sales	53.46	300.07	516.28	112.14
Price / Cash	N/A	116.33	42.23	54.60
Price / Book	1.86	6.51	9.73	6.35
Net Income	$71.18M	$24.19M	$3.57B	$337.59M
7 Day Performance	-5.54%	-6.96%	-1.28%	-2.52%
1 Month Performance	-5.37%	-2.80%	1.38%	-0.03%
1 Year Performance	-18.99%	36.80%	23.93%	25.34%

Abeona Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABEO Abeona Therapeutics	3.3469 of 5 stars	$5.46 -6.2%	$19.00 +248.0%	-19.0%	$311.19M	$5.82M	5.63	90
OCS Oculis	3.0945 of 5 stars	$14.51 -36.1%	$40.44 +178.7%	-43.7%	$1.32B	$1.45M	N/A	2	Analyst Forecast High Trading Volume
HROW Harrow	4.4214 of 5 stars	$34.11 -3.1%	$69.43 +103.5%	+12.2%	$1.31B	$268.68M	N/A	180
COAG Hemab Therapeutics	4.3577 of 5 stars	$27.13 -4.8%	$41.75 +53.9%	N/A	$1.27B	N/A	N/A	72	Quiet Period Expiration
WVE WAVE Life Sciences	2.3491 of 5 stars	$6.26 -4.9%	$27.25 +335.3%	-20.6%	$1.27B	$71.80M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABEO) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abeona Therapeutics (ABEO) Competitors

ABEO vs. OCS, HROW, COAG, WVE, and MPLT

How does Abeona Therapeutics compare to Oculis?

Summary

How does Abeona Therapeutics compare to Harrow?

Summary

How does Abeona Therapeutics compare to Hemab Therapeutics?

Summary

How does Abeona Therapeutics compare to WAVE Life Sciences?

Summary

How does Abeona Therapeutics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abeona Therapeutics (ABEO) Competitors

ABEO vs. OCS, HROW, COAG, WVE, and MPLT

How does Abeona Therapeutics compare to Oculis?

Do insiders & institutionals hold more shares of OCS or ABEO?

Which has stronger valuation and earnings, OCS or ABEO?

Do analysts recommend OCS or ABEO?

Which has more volatility & risk, OCS or ABEO?

Does the media prefer OCS or ABEO?

Is OCS or ABEO more profitable?

Summary

How does Abeona Therapeutics compare to Harrow?

Does the media refer more to ABEO or HROW?

Which has more risk & volatility, ABEO or HROW?

Is ABEO or HROW more profitable?

Which has stronger earnings and valuation, ABEO or HROW?

Do insiders and institutionals believe in ABEO or HROW?

Do analysts recommend ABEO or HROW?

Summary

How does Abeona Therapeutics compare to Hemab Therapeutics?

Is COAG or ABEO more profitable?

Which has preferable valuation and earnings, COAG or ABEO?

Do institutionals & insiders have more ownership in COAG or ABEO?

Do analysts prefer COAG or ABEO?

Does the media prefer COAG or ABEO?

Summary

How does Abeona Therapeutics compare to WAVE Life Sciences?

Do analysts prefer WVE or ABEO?

Does the media favor WVE or ABEO?

Which has stronger valuation & earnings, WVE or ABEO?

Is WVE or ABEO more profitable?

Which has more risk and volatility, WVE or ABEO?

Do institutionals and insiders have more ownership in WVE or ABEO?

Summary

How does Abeona Therapeutics compare to Maplight Therapeutics?

Do insiders and institutionals have more ownership in ABEO or MPLT?

Which has higher earnings & valuation, ABEO or MPLT?

Do analysts rate ABEO or MPLT?

Does the media refer more to ABEO or MPLT?

Is ABEO or MPLT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO vs. The Competition

Abeona Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools